GoKawiilPersonalized RNA drug shows early promise in rare ALS case
A man with a slow-progressing, genetically rare form of ALS became the first person to receive an antisense oligonucleotide therapy designed specifically to target his causal mutation. A year later, he reported improved symptoms and remains able to work as a physician, according to results published in Med.